Inhibitors of cholesteryl ester transfer protein--a new approach to coronary artery disease.
Despite the use of the statins to lower low-density lipoprotein-cholesterol, leading to major reductions in the mortality and morbidity that is associated with coronary artery disease, considerable mortality and morbidity remains. Increasing high-density lipoprotein (HDL)-cholesterol levels has been associated with reduced coronary artery disease mortality and morbidity in several studies. Inhibition of cholesteryl ester transfer protein (CETP) activity leads to increased HDL-cholesterol. In cholesterol-fed rabbits, antibodies against CETP increased HDL-cholesterol and decreased atherosclerotic lesions. In healthy subjects with mild dyslipidaemia, the CETP inhibitors JTT-705 and torcetrapib increased HDL-cholesterol and decreased low-density lipoprotein-cholesterol. Increasing HDL-cholesterol with CETP inhibitors is a new approach to dyslipidaemia that requires further investigation, especially in patients who have coronary artery disease.
Doggrell
Sheila A
SA
Division of Health Practice, Auckland University of Technology - Akoranga Campus, Northcote, Auckland, New Zealand. s.doggrell@xtra.co.nz
D000818:Animals; D000924:Anticholesteremic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002352:Carrier Proteins / Q000037:antagonists & inhibitors* / Q000097:blood; D053480:Cholesterol Ester Transfer Proteins; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy*; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006023:Glycoproteins / Q000037:antagonists & inhibitors* / Q000097:blood; D006801:Humans
D000924:Anticholesteremic Agents; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D015507:Drugs, Investigational; D006023:Glycoproteins